Clinical-stage immuno-oncology company Affimed N.V. (AFMD) Monday announced that CEO Dr. Adi Hoess will step down, effective January 15, 2024.
Dr. Hoess joined Affimed in October 2010 and has served as its Chief Executive Officer since September 2011.
The company has initiated a comprehensive search process to identify a successor CEO. In the interim, Dr. Andreas Harstrick, Chief Medical Officer of the company, will assume the role of interim CEO until a new CEO is appointed.
The company also announced a strategic restructuring, which will reduce headcount by up to 50%. The plan will extend Affimed's cash runway into second half of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.